Novo Nordisk and Merrion expand deal
This article was originally published in Scrip
Executive Summary
Novo Nordiskand Merrion Pharmaceuticalshave signed another development and licence agreement for the production of oral insulin formulations of a GLP-1 receptor agonist using the Irish company's GIPET technology. Novo Nordisk will pay Merrion $58 million for the first marketed product developed under the agreement and will be responsible for the development and commercialisation of all product candidates. Merrion will develop and manufacture initial clinical batches of the product, which will be overseen by a joint development committee. Novo Nordisk may also develop additional oral formulations of its GLP-1 receptor agonist compounds using the GIPET technology, in which case Merrion would receive additional milestone payments for any products developed. Novo Nordisk will buy 300,000 of Merrion's new ordinary shares for €3 per share. The two companies signed a development agreement for oral insulin analogues in November (ScripOnline, December 2nd, 2008).
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.